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Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive disease with symptoms that can
have a major impact on patients’ physical health. The aim of this study was to evaluate quality of life (QoL),
symptom severity and dyspnoea in COPD patients treated with aclidinium up to 24 weeks.
Methods: In this prospective non-interventional multicentre study (198 centres in Sweden, Denmark, and
Norway), COPD patients (age ]40 years) who started treatment with aclidinium (initial therapy, change of
treatment, or add-on therapy) could be included. Health-related QoL was obtained by COPD assessment test
(CAT). Symptoms were evaluated on a 6-point Likert scale. The modified Medical Research Council (mMRC)
Dyspnoea Scale was used as a simple grading system to assess the level of dyspnoea/shortness of breath from
0 to 4. Patients on treatment with aclidinium who completed baseline and at least one follow-up visit (week 12
or 24) were included in the study population.
Results: Overall, 1,093 patients were enrolled (mean 69 years, 54% females), one-third had ]1 exacerbation
the year prior to baseline. At enrolment, 48% were LAMA naı¨ve. Mean (standard deviation, SD) CAT score
decreased from 16.9 (7.7) at baseline to 14.3 (7.3) at week 24 (pB0.01) with a decrease in all individual CAT
items (pB0.05). Mean difference in morning and night-time symptoms from baseline to week 24 was 0.60
(SD 2.51) and 0.44 (SD 2.48), respectively (both pB0.001). Mean (SD) mMRC Dyspnoea Scale changed
from 1.6 (1.0) at baseline to 1.5 (1.0) at week 24 (pB0.001).
Conclusion: In this observational study of a Nordic real-life COPD population, treatment with aclidinium was
associated with a clinically important improvement in QoL and morning and night-time symptoms, most
pronounced in the LAMA naı¨ve group. However, there is still room for improvement in the management of
symptomatic COPD patients.
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C
hronic obstructive pulmonary disease (COPD) is
a major cause of morbidity and mortality world-
wide (1). As the condition progresses, the burden
and severity of symptoms increase, leading to physical
health limitations and reduced independence in activities
of daily living. Current treatment strategies aim to improve
symptom control and to reduce the risk of future exacer-
bations (1). It is recognized that the quality of an effective
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COPD management should be assessed by parameters
such as forced expiratory volume in 1 sec (FEV1), and
patient-related outcomes such as daily activities, burden
of symptoms and health-related quality of life (QoL). The
patient-reported questionnaire, COPD assessment test
(CAT) (2), has been included in the current COPD treat-
ment guidelines in addition to the disease classification by
spirometry (1).
COPD symptoms such as dyspnoea are generally
worse in the morning than during the rest of the day,
affecting morning routine activities and basic self-care
tasks (3). Patients with COPD also commonly experience
night-time symptoms that have an impact on their ability
to get up in the morning (4). Also, it has been shown that
morning symptoms may affect patients’ ability to per-
form daily life activities throughout the day (5).
Pharmacotherapy for COPD relies primarily on inhaled
medications. In a retrospective real-life study of COPD
patients in Sweden, it was shown that the introduction
of a long-acting inhaled anticholinergic agent (LAMA)
and fixed inhaled corticosteroids (ICS)/long-acting b2
agonist (LABA) combinations in COPD treatment coin-
cides with a decreased number of COPD exacerbations
over a 10-year period (6). For symptomatic patients with
low risk of exacerbations, guidelines recommend LAMA
or LABA as first-line maintenance treatment (1). In addi-
tion to current available LAMAs, aclidinium in the
Genuair inhaler is a new LAMA and the only LAMA
that is administered twice daily. In clinical studies, it has
demonstrated an effective bronchodilation, not only during
the day but also at night, resulting in a significant improve-
ment of symptoms and QoL (79).
There are limited data available about the effect of
aclidinium in a real-life COPD population. The aim of this
study was to evaluate QoL, symptom severity (including
morning and night-time symptoms), and dyspnoea in COPD
patients treated with aclidinium for up to 24 weeks.
Materials and methods
Study design and data source
This was a prospective non-interventional multicentre
study conducted at 198 primary care and specialist out-
patient centres in Sweden, Denmark, and Norway. At base-
line (visit 1), sociodemographic data (sex, age, height, and
weight) and medical data (smoking status, exacerbations,
spirometry including reversibility test, co-morbidities, and
concomitant medication) were collected. Data were regis-
tered in an electronic data capture system and stored in a
secure database managed by the Department of Applied
Mathematics and Computer Science, Technical Univer-
sity of Denmark (DTU, Copenhagen, Denmark). Patients
were asked to complete a health-related QoL question-
naire at baseline and at the 12 (visit 2) and 24 weeks (visit 3)
follow-up visits.
The study was approved by the regional ethics com-
mittee in Lund, Sweden (ref. no. 2013/499), the regional
committees for medical and health research ethics in Oslo,
Norway (ref. no. REK sør-øst 2013/1261), and permission
to compile data was granted by Danish data protection
agency in Copenhagen, Denmark (ref. no. 2013-41-2236).
All patients gave written informed consent to the doc-
umentation and processing of their data.
Study population and treatment
Male and female patients (age ]40 years) with COPD,
who started treatment with aclidinium administered ac-
cording to specifications in the summary of product char-
acteristics (322 mg aclidinium twice daily), either as initial
therapy, change of treatment or as add-on therapy could
be included in the study. The decision to initiate aclidinium
treatment had to be made prior to the decision to include
the patient into the study. The COPD diagnosis was estab-
lished according to clinical practice and a spirometry, not
older than 3 months at inclusion. Patients with pulmonary
disease other than COPD, acute COPD exacerbation within
1 month prior to inclusion, and women who were preg-
nant or breast-feeding were not eligible for inclusion. The
patient enrolment was conducted from November 2013
to December 2014.
Measurements and outcomes
Assessments
Health-related QoL was obtained from self-administered
patient questionnaires by using the Swedish, Danish, and
Norwegian versions of the CAT (2, 10). The CAT com-
prises eight items each with a scoring range of 05. The
CAT total score is derived as the sum of responses given in
the eight items with a range of 040. A minimum clinically
important improvement in CAT has been identified to
be 2.0 (11).
COPD symptoms were assessed from patient ques-
tionnaires according to five indicators: coughing during
morning, coughing during night-time, breathlessness dur-
ing morning, breathlessness during night-time, and quality
of sleep. The severity of these symptoms was evaluated on
a 6-point Likert scales rated from 0‘no symptoms’ to
5‘very severe symptoms’ and from 0‘very bad sleep’ to
5‘very good sleep’ (12).
The modified Medical Research Council (mMRC)
Dyspnoea Scale was used as a simple grading system to
assess the level of dyspnoea/shortness of breath in five
categories from 0 to 4 (1).
At each study visit, patients reported the presence of
any adverse events between visits. If judged causal to
aclidinium by the investigator, the event was reported as
an adverse drug reaction (ADR).
Peter Lange et al.
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Other measurements
Classification of patients according to GOLD AD
criteria was based on the GOLD spirometry classifica-
tions of the severity of airflow limitation, exacerbation
history in the past year, and the patient’s symptoms, using
CAT (1).
Smoking status was defined as current smoker,
ex-smoker, or never smoker.
The BMI was defined as the body weight in kilo-
grams divided by the square of height in meters.
BMI categories: underweight 518.5; normal weight
18.524.9; overweight2529.9; obesityBMI of 30 or
greater.
Lung function was defined as the percentage of FEV1
predicted value and should be no older than 3 months
prior to visit 1.
Co-morbidity was defined according to the following
selected chronic diseases: current treatment of depression,
diabetes, heart failure, ischemic heart disease, hyperten-
sion, osteoporosis, gastro-oesophageal reflux, and disease
of the musculoskeletal system (or other diseases inhibit-
ing walking).
Concomitant medications to be taken together with
aclidinium were categorized as follows: short-acting b2-
agonist (SABA), LABA, ICS, oral corticosteroids (OCS),
phosphodiesterase (PDE) 4 inhibitor, fixed ICS/LABA
combination, fixed SABA/short-acting muscarinic an-
tagonist (SAMA), other concomitant medication, or no
concomitant medication.
A combined variable regarding prior medication was
constructed based on information about treatment with
LAMA prior to inclusion (yes/no) and concomitant
maintenance medication to be taken together with
aclidinium (LABA, ICS, PDE4, and/or fixed ICS/
LABA combination). The patients were categorized into
the following four subgroups: LAMA naı¨ve without other
maintenance therapies, LAMA naı¨ve with other main-
tenance therapies, LAMA non-naı¨ve without other main-
tenance therapies, and LAMA non-naı¨ve with other
maintenance therapies. Maintenance treatment included
ICS, LABA, and LAMA.
Patient-reported satisfaction with the inhaler and
handling of the Genuair device was collected.
Statistical analysis
The study population was defined as all patients who
completed the baseline visit and at least one follow-up
visit (week 12 or 24) and continued on treatment with
aclidinium during the defined study period. Continuous
and nominal variables were described using standard
statistical measures, that is, number of observations,
mean, and standard deviation. All categorical variables
were summarized with absolute and relative frequencies.
Baseline characteristics were compared over the four
prior medication groups using one-way ANOVA tests for
continuous variables and chi-squared test for categorical
variables (and in cases where the expected numbers were
below five, Fisher’s exact test). The paired t-test was used
to compare the total CAT score and symptoms from
baseline to week 12 or baseline to week 24 to take into
account that the same group of patients were followed
through the three visits. Similarly, for categorical vari-
ables McNemar’s chi-squared test was used to compare
baseline to week 12 or 24.
An ANCOVA model was fitted to estimate the expected
changes in total CAT score for the four prior medication
groups from baseline to week 12 or 24 while taking
baseline CAT score into account. Finally, a multivariate
Number of patients Patients not completed
Baseline visit
N=1093
Week 12 visit
N=857 
Week 24 visit
N=753
n=219
Lack of effect, n=32
Adverse events*, n=32
Request by patient, n=56
Other, n=56
Lost to follow-up, n=43
n=105
Lack of effect, n=23
Adverse events*, n=44
Request by patient, n=83
Other, n=86
Lost to follow-up, n=72Study Population
n=874
Fig. 1. Patient flowchart.
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Table 1. Demographic and clinical characteristics at baseline visit among participants who completed baseline and at least one
follow-up visit (study population and subgroups based on prior medication)
Characteristics at baseline visit
Study
population
(N874)
LAMA naı¨ve
without
maintenance
(N245)
LAMA naı¨ve
with maintenance
(N172)
LAMA non-naı¨ve
without
maintenance
(N112)
LAMA non-naı¨ve
with
maintenance
(N345) pa
Country, n (%) B0.001
Sweden 497 (57) 100 (41) 79 (46) 65 (58) 253 (73)
Denmark 292 (33) 124 (51) 71 (41) 33 (29) 64 (19)
Norway 85 (10) 21 (9) 22 (13) 14 (12) 28 (8)
Gender, n (%) 0.069
Men 398 (46) 120 (49) 89 (52) 47 (42) 142 (41)
Age (years), mean (SD) 69.3 (9.1) 67.8 (9) 68.7 (10) 68.8 (9.4) 70.9 (8.4) B0.001
Age categories (years), n (%) 0.002
4049 25 (3) 10 (4) 9 (5) 1 (1) 5 (1)
5059 105 (12) 35 (14) 23 (13) 20 (18) 27 (8)
6069 298 (34) 93 (38) 55 (32) 42 (38) 108 (31)
7079 332 (38) 85 (35) 59 (34) 36 (32) 152 (44)
80 114 (13) 22 (9) 26 (15) 13 (12) 53 (15)
Smoking status, n (%) B0.001
Current smoker 314 (36) 127 (52) 58 (34) 41 (37) 88 (26)
Ex-smoker 527 (60) 111 (45) 104 (60) 65 (58) 247 (72)
Never smoker 33 (4) 7 (3) 10 (6) 6 (5) 10 (3)
BMI, mean (SD) 26.2 (5.2) 26.3 (5.5) 26.4 (4.8) 26.6 (5.7 25.9 (5.1) 0.542
BMI, n (%) 0.812
Underweight 48 (5) 12 (5) 6 (3) 7 (6) 23 (7)
Normal weight 342 (39) 100 (41) 64 (37) 38 (34) 140 (41)
Overweight 287 (33) 80 (33) 59 (34) 39 (35) 109 (32)
Obesity 197 (23) 53 (22) 43 (25) 28 (25) 73 (21)
FEV1 (% predb), mean (SD) 54.9 (16.3) 61.5 (14.6) 56.2 (16.2) 59.0 (14.9) 48.3 (15.5) B0.001
FEV1 (% predb), n (%) B0.001
B30% 59 (7) 4 (2) 8 (5) 4 (4) 43 (12)
30 to B50% 261 (30) 47 (19) 48 (28) 24 (21) 142 (41)
50 to B80% 494 (57) 169 (69) 104 (60) 73 (65) 148 (43)
80% 60 (7) 25 (10) 12 (7) 11 (10) 12 (3)
GOLD AD,c n (%) B0.001
A 87 (10) 39 (16) 11 (6) 14 (12) 23 (7)
B 368 (42) 137 (56) 79 (46) 53 (47) 99 (29)
C 48 (5) 8 (3) 11 (6) 9 (8) 20 (6)
D 371 (42) 61 (25) 71 (41) 36 (32) 203 (59)
Exacerbations 1 year prior to
baseline, n (%)
B0.001
0 537 (61) 185 (76) 98 (57) 68 (61) 186 (54)
1 205 (23) 45 (18) 48 (28) 27 (24) 85 (25)
2 78 (9) 11 (4) 14 (8) 12 (11) 41 (12)
]3 54 (6) 4 (2) 12 (7) 5 (4) 33 (10)
Co-morbidities, n (%) 0.129
Depression 66 (8) 19 (9) 8 (5) 10 (9) 29 (7)
Diabetes 98 (11) 27 (12) 23 (14) 17 (15) 31 (8)
CV (heart failure or ischemic
disease)
154 (18) 29 (13) 31 (19) 17 (15) 77 (19)
Hypertension 330 (38) 92 (43) 61 (37) 42 (36) 135 (34)
Osteoporosis 76 (9) 13 (6) 13 (8) 10 (9) 40 (10)
Peter Lange et al.
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logistic regression model was used to estimate the odds of
reaching a clinically important difference of at least two
units on total CAT score from baseline to week 12. This
model included the covariates: baseline CAT score, age,
sex, current smoker (yes/no), BMI group (underweight,
normal, overweight/obese), FEV1 ]50% of the predicted
value (yes/no), heart failure or ischemic disease (yes/no),
and prior medication.
Results
Patient flow
A total of 1,093 patients were enrolled across the 198
study sites in Sweden, Denmark, and Norway. Follow-up
visits were completed for 78% (n857) of the enrolled
patients at week 12 and 69% (n753) at week 24 (Fig. 1).
Overall, 80% (n874) completed the baseline visit and at
least one follow-up visit, and thus comprised the study
population.
Baseline characteristics
Mean age was 69 years and 54% were females (Table 1).
The majority had a history of smoking (96% current or
ex-smokers) and more than half of the patients (56%)
were overweight or obese. Baseline lung function mea-
sured within 3 months prior to study enrolment showed a
mean FEV1 percentage of predicted normal of 55%.
One-third of the patients had experienced one or more
exacerbations during the year prior to baseline. The
majority of the patients were classified as either GOLD
B (42%) or GOLD D (42%). The leading co-morbidity
was hypertension (37%) followed by ischemic disease
(12%) and diabetes mellitus (11%) (Table 1). No differ-
ences were seen regarding baseline patient characteristics
between the patients included in the study population
and the patients who were lost to follow-up (results not
shown).
During enrolment, 52% (n457) of the patients were
switched from another LAMA medication and 48%
(n417) were new initiated to aclidinium. The proportion
of patients in each of the four subgroups based on prior
medication was 20% LAMA naı¨ve with maintenance,
28% LAMA naı¨ve without maintenance, 39% LAMA
non-naı¨ve with maintenance, and 13% LAMA non-naı¨ve
without maintenance (Table 1). Compared to participants
without maintenance medication, those on maintenance
medication had a lower FEV1 in % of predicted value
and more of them belonged to GOLD D group (Table 1).
Two-thirds of the patients used aclidinium as add-on
therapy; the most frequent maintenance medication was
fixed ICS/LABA combinations (32%), followed by LABA
(10%). In addition, 27% of the patients used SABA.
Table 1 (Continued )
Characteristics at baseline visit
Study
population
(N874)
LAMA naı¨ve
without
maintenance
(N245)
LAMA naı¨ve
with maintenance
(N172)
LAMA non-naı¨ve
without
maintenance
(N112)
LAMA non-naı¨ve
with
maintenance
(N345) pa
Gastro-oesophageal reflux 75 (9) 11 (5) 11 (7) 11 (9) 42 (11)
Disease of the musculoskeletal
system
97 (11) 25 (12) 17 (10) 10 (9) 45 (11)
Baseline concomitant
medication, n (%)
SABA 333 (27) 62 (25) 70 (27) 49 (41) 152 (26)
LABA 126 (10) 0 (0) 53 (20) 0 (0) 73 (12)
ICS 57 (5) 0 (0) 23 (9) 0 (0) 34 (6)
Oral steroids 14 (1) 3 (1) 0 (0) 5 (4) 6 (1)
PDE4 inhibitor 16 (1) 0 (0) 1 (0) 0 (0) 15 (3)
Fixed ICS/LABA combination 392 (32) 0 (0) 107 (41) 0 (0) 285 (48)
Fixed SABA/SAMA
combination
10 (1) 1 (0) 0 (0) 2 (2) 7 (1)
Other 39 (3) 7 (3) 7 (3) 6 (5) 19 (3)
No concomitant medication 232 (19) 175 (71) 0 (0) 57 (48) 0 (0)
Switch from other LAMA, n (%)
Yes 457 (52) 0 (0) 0 (0) 112 (100) 345 (100)
ap-Value for difference in prior medication by chi-squared test (categorical) and ANOVA (continuous).
bPercentage of forced expiratory volume in 1 sec (FEV1) predicted value.
cGOLD spirometry classifications based on the severity of airflow limitation, exacerbation history in the past year, and the patient’s
symptoms.
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Health-related QoL (CAT)
The mean (SD) CAT total score changed significantly
from 16.9 (7.7) at baseline to 14.6 (7.3) points at week 12,
and to 14.3 (7.3) at week 24 (pB0.01 for both). Figure 2
shows the changes in the total score and in the individual
CAT item scores. All individual CAT item scores
decreased significantly from baseline (pB0.05; Fig. 2)
with the largest mean improvement in the item ‘breathless
when walking up a hill or one flight of stairs’.
A clinically relevant improvement in the total CAT
score (minimal clinically important difference by at least
two points) was observed in 55% for the patients with
complete CAT data available. The estimated improve-
ment in total CAT score was highest in the LAMA naı¨ve
patients without maintenance treatment; while control-
ling for baseline CAT score, the mean change at week 12
was 3.5 (95% confidence interval [CI] 4.2 to 2.9)
and at week 24 3.8 (95% CI 4.6 to 3.1) (Table 2).
Looking at the pairwise comparisons between the
four groups at week 12, the improvement in the LAMA
naı¨ve without maintenance treatment was significantly
higher than in the two LAMA non-naı¨ve groups (with
maintenance pB0.01, without maintenance p0.04
[data not shown]).
Predictors of improvement in CAT total score
The results from the multivariate logistic regression
(Table 3) shows that prior medication was the strongest
predictor of reaching a clinically relevant improvement of
at least two units on the total CAT score from baseline
to week 12 (pB0.01). Compared to the LAMA non-naı¨ve
with maintenance, the LAMA naı¨ve groups have sig-
nificantly higher odds of improving when adjusting for
baseline CAT score, sex, age, smoking status, BMI group,
FEV1, and cardio vascular disease (odds ratio [OR]
1.9 (95% CI 1.32.9) for naı¨ve with maintenance and
OR 1.8 [95% CI 1.32.7] without maintenance). Also,
higher baseline CAT score and FEV150% of predicted
value were significant predictors of clinically relevant
improvement in CAT.
Severity of morning and night-time symptoms
The proportion of patients with no morning symptoms
changed from 35% at baseline to 45% at week 12, and to
42% at week 24 (Fig. 3). Moderate-to-very severe
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morning symptoms were reported by 40% of the patients
at baseline and by 31% after 24 weeks of follow-up
(Fig. 3). The proportion of patients with no night-time
symptoms was 48% at baseline, 57% at week 12, and 54%
at week 24 (Fig. 3). Moderate-to-very severe night-time
symptoms were observed for 31% of the patients at
baseline and for 23% after 24-week follow-up (Fig. 3).
There was a statistically significant improvement in
morning and night-time symptoms (any symptom,
cough, breathlessness, or/and sleep quality) (pB0.001;
Fig. 4). The largest improvement was found for ‘morning
symptoms (any)’: week 12: mean difference of 0.68
(SD 2.34) and week 24 mean difference of 0.60 (SD
2.51). Further, a statistically significant improvement in
all subgroups except LAMA non-naı¨ve patients without
maintenance was observed for morning and night-time
symptoms (Table 4).
Breathlessness (the mMRC Dyspnoea Scale)
The mean (SD) mMRC Dyspnoea Scale changed sig-
nificantly (pB0.001) from 1.6 (1.0) at baseline to 1.5 (1.0)
at weeks 12 and 24 (Table 5). The proportion of patients
with an mMRC grade ]2 changed from 52% at baseline
to 45% at week 12 and 42% at week 24 (Table 5).
Adverse drug reactions
During this 6-month study, 46 patients (4%) reported in
total 102 ADRs, whereof 29 were reported as serious
adverse events. Overall, 33 patients discontinued study
drug due to ADR. The most commonly reported ADR
was dysphonia (0.9%), unpleasant product taste (0.7%),
headache (0.7%), dyspnoea (0.5%), and nausea (0.5%).
All other ADRs reported had an incidence of B0.5%.
One serious adverse event was fatal (cardiac arrest),
however, without reported drug causality.
Patient handling and satisfaction of the Genuair
device
Overall, 95% of the patients found the Genuair device
easy or very easy to use and 68% of the patients were
satisfied or very satisfied with the device.
Discussion
In this real-life COPD population recruited from general
practice and outpatient specialist care, including both
LAMA-naı¨ve patients and LAMA switchers, both with
and without concurrent COPD maintenance medications,
treatment with aclidinium during 24 weeks was asso-
ciated with a significant improvement in both QoL and
in early morning and night-time COPD symptoms.
Table 2. Estimated change in CAT total score from baseline to week 12 and from baseline to week 24 adjusting for baseline
CAT score with test for effect of prior medication
Change from baseline to week 12 Change from baseline to week 24
Prior medication Estimated change (95% CI) p Estimated change (95% CI) p
LAMA naive without maintenance 3.54 (4.21; 2.86) 0.0296 3.82 (4.58; 3.05) 0.0410
LAMA naive with maintenance 2.75 (3.55; 1.95) 3.31 (4.23; 2.38)
LAMA non-naive without maintenance 1.90 (2.89; 0.90) 2.85 (3.95; 1.74)
LAMA non-naive with maintenance 1.39 (1.96; 0.83) 1.41 (2.04; 0.78)
Sample size: n774 (week 12) and n679 (week 24).
Table 3. Predictors of improvement in CAT total score (at
least two points) from baseline to week 12 (multivariate
logistic regression)
CAT total score
improvement
(at least two points)
OR (95% CI) p
CAT baseline scorea 1.10 (1.08; 1.13) B0.01
Women 1.26 (0.95; 1.69) 0.11
Men (ref.)
Age (years) 1.00 (0.98; 1.02) 0.87
Current smoker (baseline) 0.87 (0.63; 1.20) 0.41
Not current smoker (baseline) (ref.)
BMI (baseline)
Underweight 1.39 (0.72; 2.74) 0.54
Normal (ref.)
Overweight or obese 1.12 (0.83; 1.52)
FEV1 ]50% (baseline) 1.57 (1.14; 2.16) 0.01
FEV1 B50% (baseline) (ref.)
CV co-morbidityb (baseline) 0.83 (0.57; 1.23) 0.36
No CV co-morbidity (baseline) (ref.)
Prior medication (baseline)
LAMA naive without
maintenance
1.84 (1.26; 2.71) B0.01
LAMA naive with
maintenance
1.95 (1.30; 2.95)
LAMA non-naive without
maintenance
1.19 (0.75; 1.91)
LAMA non-naive with
maintenance
(ref.)
aCOPD assessment test measured at baseline visit.
bCV comorbidityheart failure or ischemic disease.
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Fig. 3. Prevalence of morning and night-time COPD symptoms (any) at baseline, week 12, and week 24.
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versus follow-up (weeks 12 and 24).
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The most pronounced improvement was observed after
12 weeks, whereas the difference between weeks 12 and
24 was smaller. This indicates an effect within 12 weeks,
with the greatest improvement seen in the LAMA-naı¨ve
patients. However, approximately one out of four patients
still experienced moderate-to-very severe morning and
night-time symptoms at follow-up, indicating suboptimal
symptom control.
Overall, the addition of a LAMA to ICS and/or LABA
treatment was associated with a beneficial effect, but the
most important predictor of improvement in CAT score
was being LAMA naı¨ve.
The beneficial effect of adding a LAMA to ICS/LABA
treatment has previously been reported in randomized
clinical trials (13, 14). In the present study, almost half of
the patients were LAMA naı¨ve at baseline, fewer than in
previous studies (8, 15). In the recently published
Austrian real-life study with a similar design (n795,
12-week follow-up, mean age 64 years, 44% female), three
out of four patients were LAMA naı¨ve at baseline (16).
The improvements in CAT, mMRC Dyspnoea Scale,
and symptoms observed in that study were greater than
what was seen in the present study, which may be
explained by the slightly younger study population and
the fact that the majority of the patients in that study
were LAMA naı¨ve.
The literature suggests that COPD symptoms are worst
during morning, with four out of five COPD patients
experiencing shortness of breath in the morning (17).
Night-time symptoms are also prevalent and have been
Table 4. Subgroup analysis of change in morning symptoms, night-time symptoms, and mMRC Dyspnoea Scale from baseline
versus week 12 and baseline versus week 24 according to prior medication
Prior medication
LAMA naive without
maintenance
LAMA naive with
maintenance
LAMA non-naive
without maintenance
LAMA non-naive with
maintenance
Difference in
means (SD)
Difference in
means (SD)
Difference in
means (SD)
Difference in
means (SD)
Change from baseline vs. week 12
Morning symptoms (any) 0.9 (2.3)a 0.8 (2.3)a 0.5 (2.5)a 0.6 (2.0)a
Night-time symptoms (any) 0.8 (2.2)a 0.6 (2.4)a 0.3 (2.4) 0.5 (2.3)b
mMRC dyspnoea grade 0.0 (0.9) 0.3 (0.9)a 0.1 (0.9) 0.3 (0.9)a
Change from baseline vs. week 24
Morning symptoms (any) 0.9 (2.5)a 0.8 (2.4)a 0.3 (2.6) 0.7 (2.2)a
Night-time symptoms (any) 0.8 (2.3)a 0.5 (2.5)a 0.2 (2.7) 0.6 (2.2)b
mMRC dyspnoea grade 0.2 (0.8)b 0.3 (0.9)a 0.1 (0.9) 0.4 (0.8)a
Sample size: n774 (week 12) and n679 (week 24).
apB0.01 for baseline versus follow-up (weeks 12 and 24); bpB0.05 for baseline versus follow-up (weeks 12 and 24).
Table 5. Proportion of patients (%) at each mMRC dyspnoea grade from 0 to 4 at baseline (N797), week 12 (N774), and
week 24 (N679)
Baseline Week 12 p Week 24 p
mMRC grade, mean (SD) 1.6 (1.0) 1.5 (1.0) 1.5 (1.0)
Difference in means (SD) 0.2 (0.9) B0.001 0.2 (0.9) B0.001
mMRC grade, n (%)
Grade 0 98 (12.3) 122 (15.8) 109 (16.1)
Grade 1 274 (34.4) 284 (36.7) 258 (38.0)
Grade 2 254 (31.9) 215 (27.8) 179 (26.4)
Grade 3 135 (16.9) 112 (14.5) 92 (13.5)
Grade 4 29 (3.6) 19 (2.5) 16 (2.4)
Missing 7 (0.9) 22 (2.8) 25 (3.7)
mMRC grade ] 2, n (%) 418 (52.4) 345 (44.6) B0.001 287 (42.3) B0.001
Respondents with ‘missing’ are not included in calculating p values.
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associated with worsening of COPD severity (18), risk of
future exacerbations (19), poor QoL (20, 21), increased
anxiety and depression (22), and mortality (23, 24).
Furthermore, it has been shown that patients commonly
take their medication too late in the morning to have an
effect on morning symptoms (17). The LAMAs available
for the treatment of COPD have a once-daily regimen,
except for aclidinium which is administered twice daily.
Patient preference regarding dosing regimens varies, as
shown in a recent study on asthma and COPD patients
where only half of the patients actually preferred the
once-daily regimen (25). In addition, significant improve-
ments in night-time symptom severity were shown for
aclidinium but not for tiotropium compared to placebo
(8). Also, a mean FEV1 below baseline was reported for
tiotropium during a prolonged period of the night com-
pared to aclidinium (8). For the LAMA-naı¨ve patients in
the present study, a positive effect on health status would
likely be observed by adding any LAMA. For patients
switched from another LAMA to aclidinium, the positive
effect on symptoms may be explained by the twice daily
dosing of aclidinium, potentially increased by a placebo
effect due to study participation.
The main limitation of the present study is the observa-
tional design with the absence of a control group. The
association found may have been affected by other factors
impacting patient-reported outcomes, such as participa-
tion in a study. No information regarding the reason for
the patients’ visit to the physician during which aclidinium
was initiated was collected (scheduled follow-up visit or a
visit due to disease deterioration) and patient adherence
to treatment was not monitored. Furthermore, two-thirds
of the patients used aclidinium as add-on therapy and
it cannot be ignored that the use of concomitant main-
tenance medications for COPD may have influenced the
results. Bias due to the unknown disease severity of the
patients lost to follow-up cannot be excluded; however,
a comparison of patient characteristics between the
study population and the lost to follow-up population
showed similar groups at baseline. Approximately, 5% of
the recruited patients were excluded from the study before
the week 24 visit due to lack of medication effect, and
as these patients are not included in the study population,
our results are slightly skewed towards favouring the effect
of aclidinium.
However, as most pivotal pharmacological trials ex-
clude patients suffering from significant co-morbidities,
the real-life character of the present study expands
currently available knowledge, which is derived almost
exclusively from controlled randomized trials, performed
in highly selected patients by narrow inclusion criteria,
resulting in low external validity.
The safety data obtained in this study are consistent
with the safety and tolerability data reported in other
studies (7, 8, 16).
Conclusion
In this observational study of a Nordic real-life COPD
population recruited from general practice and outpatient
specialist care, we found that that treatment with aclidi-
nium was associated with a significant and clinically
important improvement in QoL and in morning and
night-time symptoms after 12 weeks, primarily in LAMA-
naı¨ve patients but also in non-naı¨ve patients. However,
as a proportion of patients still experienced moderate-
to-very severe morning and night-time symptoms at study
end, there is still room for improvement in the everyday
management of symptomatic patients with COPD.
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